Effect of meropenem against multidrug-resistant Mycobacterium tuberculosis

Journal of Chemotherapy

Volumn 20, Issue 3, 2008, Pages 395-396

  Coban, A Y ^a   Bilgin, K ^a   Tasdelen Fisgin, N ^a   Uzun, M ^b   Durupinar, B ^a  

^a ONDOKUZ MAYIS UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMPICILLIN; ETHAMBUTOL; IMIPENEM; ISONIAZID; MEROPENEM; RIFAMPICIN; STREPTOMYCIN; SULTAMICILLIN;

ACCURACY; ANTIBIOTIC SENSITIVITY; BACTERIAL STRAIN; BACTERIUM ISOLATE; DRUG EFFECT; LETTER; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; REPRODUCIBILITY;

EID: 47349123717     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2008.20.3.395     Document Type: Letter

References (12)

1. Chambers HF, Turner J, Schecter GF, Kawamura M, Hopewell PC. Imipenem for treatment of tuberculosis in mice and humans. Antimicrob Agents Chemother 2005; 49: 2816-2821.
2. Segura C, Salvado M, Collado I, Chaves J, Coira A. Contribution of β-lactamases to β-lactam susceptibilities of susceptible and multidrug-resistant Mycobacterium tuberculosis clinical isolates. Antimicrob Agents Chemother 1998; 42: 1524-1526.
3. Hackbarth CJ, Unsal I, Chambers HF. Cloning and sequence analysis of a class A β-lactamase from Mycobacterium tuberculosis H37Ra. Antimicrob Agents Chemother 1997; 41: 1182-1185.
4. Dincer I, Ergin A, Kocagoz T. The in vitro efficacy of β-lactam and β-lactamase inhibitors against multidrug resistant clinical strains of Mycobacterium tuberculosis. Int J Antimicrob Agents 2004; 23: 408-411.
5. Lowe MN, Lamb HM. Meropenem: an updated review of its use in the management of intra-abdominal infections. Drugs 2000; 60: 619-646.
6. Watt B, Edwards JR, Rayner A, Grindey AJ, Harris G. In vitro activity of meropenem and imipenem against mycobacteria: development of a daily antibiotic dosing schedule. Tuber Lung Dis 1992; 73: 134-136.
7. Etest Technical Booklet for Mycobacterium tuberculosis 2005, AB BIODISK, Solna, Sweeden.
8. Paramasivan CN, Venkataraman P, Herbert D. Minimal inhibitory concentrations of sulbactam/ampicillin against drug sensitive and drug resistant isolates of Mycobacterium tuberculosis. Microbios 1997; 89: 135-141.
9. Chambers HF, Kocagoz T, Sipit T, Turner J, Hopewell PC. Activity of amoxicillin/clavulanate in patients with tuberculosis. Clin Infect Dis 1998; 26: 874-877.
10. Cynamon MH, Palmer GS. In vitro activity of amoxicillin in combination with clavulanic acid against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1983; 24: 429-431.
11. Sorg TB, Cynamon MH. Comparison of four beta-lacta-mase inhibitors in combination with ampicillin against Mycobacterium tuberculosis. J Antimicrob Chemother 1987; 19: 59-64.
12. Tamas F. Use of amikacin and amoxicillin-clavulanic acid against Mycobacterium tuberculosis. Chest 1993; 104: 328.